STAT+: Moderna CEO on what’s next after success in cancer vaccine — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Moderna completed a decade-long development of intismeran, an mRNA-based personalized cancer vaccine, culminating in the first successful Phase 3 trial showing improved outcomes for melanoma patients
- Stéphane Bancel expressed pride in the achievement, noting that many in the field doubted mRNA cancer vaccines would work despite prior failed attempts by others
- Moderna and Merck jointly advanced intismeran through clinical development, marking a pivotal outcome in their collaboration to target solid tumors with mRNA technology
- Intismeran demonstrated efficacy in a Phase 3 study presented at the European Society of Medical Oncology annual meeting in Madrid, a milestone for personalized cancer therapies
- Bancel highlighted that the success validates Moderna’s broader R&D strategy beyond infectious diseases, reshaping the company’s long-term business trajectory
Why it matters: The trial’s success gives Moderna a validated platform in oncology, a high-stakes market where few personalized vaccines have advanced this far. With Merck as a key partner, the company now has leverage to expand mRNA into new indications, shifting investor expectations from pandemic-era biotech to durable therapeutic innovation.
Ask SkimNews
